SANJAY CHANDRAGIRI: Open Payments
NPI 1467433060 · DUNMORE, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$74,237 in 196 payments from 15 companies in 2025. Trend: 2023 $83,745 · 2024 $49,965 · 2025 $74,237
Speaker / faculty: $58,095Consulting: $6,799Travel & lodging: $4,949Food & beverage: $4,394
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 39 | $28,575 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 34 | $25,276 |
| Janssen Pharmaceuticals, Inc | 20 | $13,125 |
| ABBVIE INC. | 15 | $5,763 |
| Neurocrine BioSciences, Inc. | 25 | $431 |
| Teva Pharmaceuticals USA, Inc. | 14 | $185 |
| Otsuka America Pharmaceutical, Inc. | 8 | $180 |
| Alkermes, Inc. | 8 | $173 |
| Lundbeck LLC | 11 | $148 |
| Axsome Therapeutics, Inc. | 5 | $87 |
Products named: FANAPT, CAPLYTA, SPRAVATO, VRAYLAR, INGREZZA, REXULTI, ARISTADA, AUSTEDO XR.
Industry payments across PA — which companies pay providers there.
